A new study led by Prof. Tan Zhiliang from the Institute of Subtropical Agriculture of the Chinese Academy of Sciences has ...
Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...
Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.